8-K: Beneficient Secures $1.91 Million Primary Capital Through New Convertible Preferred Stock Issuance

Beneficient has successfully closed a $1.91 million primary capital transaction by issuing Series B-8 Resettable Convertible Preferred Stock, expanding its alternative asset financing solutions.

Summary

• Beneficient closed a $1.91 million primary capital transaction on June 17, 2025, involving a limited partner interest in an investment fund with a net asset value of $1,910,370.
• In exchange for the limited partner interest, the customer received 191,037 shares of Beneficient's Series B-8 Resettable Convertible Preferred Stock.
• The Series B-8 Preferred Stock is convertible into Class A Common Stock at an initial conversion price of $0.3397 per share, subject to monthly resets with a floor price of $0.2548 per share.
• A maximum of 7,497,528 shares of Class A Common Stock may be issued upon conversion of the Series B-8 Preferred Stock.
• This transaction marks the Company's third GP Primary transaction of the fiscal year and fourth since the program's formal launch in late 2024.
• Concurrently, the Company entered into a Preferred Liquidity Provider Program Agreement with the Fund, aiming to facilitate ongoing liquidity solutions for the Fund and its limited partners.

Sentiment

Score: 6

Explanation: The transaction represents a successful execution of the company's strategic program, securing new capital and increasing collateral. However, the terms of the preferred stock introduce potential dilution and conversion limitations, which could be viewed cautiously by investors.

Positives

• Successfully closed a $1.91 million primary capital transaction, demonstrating continued momentum in its GP Primary Commitment Program.
• The transaction is the third GP Primary transaction of the fiscal year and fourth since the program's late 2024 launch, indicating successful execution of a strategic initiative.
• The transaction is expected to increase the collateral for the Company's ExAlt loan portfolio by approximately $1.91 million.
• The Company entered into a Preferred Liquidity Provider Program Agreement, which could facilitate ongoing liquidity solutions for the Fund and its limited partners, potentially expanding future business.
• The GP Primary Commitment Program targets a significant market demand, estimated at up to $330 billion for primary commitments.

Negatives

• The issuance of 191,037 shares of Series B-8 Resettable Convertible Preferred Stock, convertible into up to 7,497,528 shares of Class A Common Stock, introduces potential significant dilution for existing shareholders.
• The Series B-8 Preferred Stock ranks junior to the Company's Series A, B-1 through B-7 Convertible Preferred Stock and all existing and future indebtedness, placing it lower in the capital structure hierarchy.
• Conversion of the Series B-8 Preferred Stock is subject to an "Exchange Cap" under Nasdaq rules, requiring stockholder approval for issuances exceeding this cap, which could delay full conversion.
• A 4.99% "Beneficial Ownership Limitation" for any single holder can also delay conversions, potentially limiting immediate liquidity for preferred stockholders.

Risks

• Forward-looking statements in the report are subject to risks and uncertainties that could significantly affect expected results, as detailed in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
• The issuance of Class A Common Stock upon conversion of the Series B-8 Preferred Stock may be limited by the Nasdaq "Exchange Cap," requiring stockholder approval for conversions exceeding this limit, which could delay or prevent full conversion.
• Conversions are also subject to a 4.99% "Beneficial Ownership Limitation," which may delay a holder's ability to convert their preferred shares into common stock.

Future Outlook

The Company intends to continue pursuing additional opportunities that align with its strategic vision and growth objectives, particularly within its GP Primary Commitment Program, which aims to address a significant market demand for primary capital solutions.

Management Comments

• "We are excited to continue recent momentum by completing another GP primary capital transaction, our second transaction with a fund managed by the Fund Manager."
• "We will continue to pursue additional opportunities that align with our strategic vision and growth objectives."

Industry Context

Beneficient operates a technology-enabled platform, AltAccess, providing exit opportunities and primary capital solutions, along with trust and custody services, for alternative assets. This transaction is part of its "GP Primary Commitment Program," which focuses on providing capital and financing anchor commitments to general partners during their fundraising efforts. This positions Beneficient as a liquidity provider in the alternative asset market, addressing a potential demand of up to $330 billion for such primary commitments.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the conversion of Series B-8 Preferred Stock into Class A Common Stock, especially given the resettable conversion price with a floor.
• Investors (Series B-8 Preferred Stock Holders): Receive a new class of preferred stock with specific conversion rights, but face potential delays in conversion due to Nasdaq Exchange Cap and Beneficial Ownership Limitations.
• Company: Secures additional capital and increases collateral for its loan portfolio, supporting its strategic growth in alternative asset financing.
• Customers (Investment Fund): Received primary capital, enabling their fundraising efforts and potentially benefiting from the Preferred Liquidity Provider Program Agreement.

Next Steps

• The Company will file a preliminary and definitive proxy statement with the SEC to seek stockholder approval for issuing Class A Common Stock upon conversion of the Series B-8 Preferred Stock in excess of the Nasdaq Exchange Cap.
• The Company plans to continue pursuing additional opportunities that align with its strategic vision and growth objectives, particularly within its GP Primary Commitment Program.

Key Dates

Recommendation

Keywords

Beneficient, BENF, SEC Filing, 8-K, Convertible Preferred Stock, Capital Raise, Equity Issuance, Alternative Assets, GP Primary Transaction, Financial Services, Nasdaq, Dilution, Corporate Governance, Preferred Stock